-The Times of India NEW DELHI: The drug price regulator has mandated companies to seek its approval for every new medicine, including combinations of existing ones, to ensure that consumers are not overcharged. According to the National Pharmaceutical Pricing Authority (NPPA) all innovative launches like new combinations of price-controlled medicines as well as those with changed strengths and dosages will be treated as 'new medicines'. The move is aimed at spanning the...
More »SEARCH RESULT
Total Matching Records found : 124
Doesn't India Already Have an IPR Policy? -Sunil Mani
-Economic and Political Weekly The National Democratic Alliance government has constituted the IPR Think Tank which, among other things, is to draft the National Intellectual Property Rights Policy. India may not have a policy per se but it has a strong legislation on IPRs, a functioning patents office and mechanisms to grant patents as well as protect consumer interests. The Think Tank has other issues it needs to address, but is...
More »Made for Big Pharma -Paranjoy Guha Thakurta
-Deccan Chronicle Prime Minister Narendra Modi may be patting himself on the back because President Barack Obama has agreed to India's position on food stockholding norms in World Trade Organisation (WTO). However, New Delhi seems to be bending over backwards to accommodate the American government and giant multinational corporations (MNCs) in the pharmaceutical industry, which will work to the detriment of our country's interests. In less than six months, the Modi government...
More »From January 2015, life-saving drugs to show govt-fixed rates in bold red -Sushmi Dey
-The Times of India NEW DELHI: All life saving drugs from January 2015 will come with a bold red strip on their packs highlighting price as fixed by the government and also specify if they are under price control. Signaling a New Year gift for consumers, the government is set to make it mandatory for regulated drugs to print on their packs 'DPCO Scheduled Drug' in black ink on a bold...
More »Mala Fide Decision on Drug Prices
-Economic and Political Weekly The decision to reduce the powers of the drug pricing body goes against the interest of public health. The decision of the Government of India to withdraw the power of the National Pharmaceutical Pricing Authority (NPPA) to set price controls on drugs that are not on the National List of Essential Medicines (NLEM) raises questions on the Narendra Modi regime's commitment to people's welfare. One must ask if...
More »
